PRINCETON, New Jersey and MUMBAI, India, July 11, 2018 /PRNewswire/ --
DUSA Pharmaceuticals, Inc., ("DUSA") a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) announced that DUSA has filed trade secret misappropriation and tortious interference claims in an ongoing patent infringement lawsuit against Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG in the United States District Court for the District of Massachusetts. The lawsuit alleges patent infringement of DUSA's patents, US 9,723,991 and US 8,216,289 covering DUSA's product, LEVULAN® KERASTICK® (aminolevulinic acid HCl) for topical solution, 20% used with DUSA's BLU-U Blue Light Photodynamic Therapy Illuminator.
(Logo: https://mma.prnewswire.com/media/717258/Sun_Pharma_Logo.jpg )
In its amended complaint, DUSA additionally alleges that the Biofrontera defendants misappropriated confidential and trade secret information from DUSA and improperly obtained confidential DUSA information from former DUSA employees to sell and market defendants' own products. The lawsuit seeks an assessment of both damages and injunctive relief against the Biofrontera defendants.
The patents-in-suit concern an apparatus and method for "photodynamic therapy" (or "PDT") and equipment for PDT. The photodynamic therapy, pioneered by DUSA, combines a drug with a light source to treat disease conditions. The product was launched by DUSA in September 2000 in the US.
Disclaimer:
Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):
Sun Pharma is the world's 5th largest specialty generic pharmaceutical company and India's top pharmaceutical company. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 41 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.
For further information:
Please visit http://www.sunpharma.com
Please visit http://www.dusapharma.com/
Follow us on Twitter @SunPharma_Live
SOURCE Sun Pharmaceutical Industries Ltd
Advertisement
DUSA Pharmaceuticals, Inc., ("DUSA") a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) announced that DUSA has filed trade secret misappropriation and tortious interference claims in an ongoing patent infringement lawsuit against Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG in the United States District Court for the District of Massachusetts. The lawsuit alleges patent infringement of DUSA's patents, US 9,723,991 and US 8,216,289 covering DUSA's product, LEVULAN® KERASTICK® (aminolevulinic acid HCl) for topical solution, 20% used with DUSA's BLU-U Blue Light Photodynamic Therapy Illuminator.
Advertisement
(Logo: https://mma.prnewswire.com/media/717258/Sun_Pharma_Logo.jpg )
In its amended complaint, DUSA additionally alleges that the Biofrontera defendants misappropriated confidential and trade secret information from DUSA and improperly obtained confidential DUSA information from former DUSA employees to sell and market defendants' own products. The lawsuit seeks an assessment of both damages and injunctive relief against the Biofrontera defendants.
The patents-in-suit concern an apparatus and method for "photodynamic therapy" (or "PDT") and equipment for PDT. The photodynamic therapy, pioneered by DUSA, combines a drug with a light source to treat disease conditions. The product was launched by DUSA in September 2000 in the US.
Disclaimer:
Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):
Sun Pharma is the world's 5th largest specialty generic pharmaceutical company and India's top pharmaceutical company. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 41 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.
For further information:
Please visit http://www.sunpharma.com
Please visit http://www.dusapharma.com/
Follow us on Twitter @SunPharma_Live
SOURCE Sun Pharmaceutical Industries Ltd
